No Data
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $50 to $65
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
TD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)
Protagonist Therapeutics: Promising Growth With ICONIC Phase 3 Success and Strategic Partnerships
Express News | Protagonist Therapeutics Inc Shares Down 5.9% at $38 in Relatively Light Trading Volume After the Bell Following Update From Phase 3 Study of Plague Psoriasis Treatment
Express News | Protagonist Therapeutics-Iconic-Lead Achieved Its Co-Primary Endpoints of Pasi-90 and Iga of 0 or 1 at Week 16
No Data
No Data